The composition of any one of claims 1-4, wherein the antibody, or antigen binding portion thereof, dissociates from the p40 subunit of IL-12 with a K<sub>d </sub>of 1×10<sup>−10 </sup>M or less or a K<sub>off </sub>rate constant of 1×10<sup>−3 ed by surface plasmon resonance. view more

A neutralizing isolated human antibody, or antigen-binding portion thereof that binds to human IL-12 and disassociates from human IL-12 with a K<sub>off </sub>rate constant of 1×10<sup>−2</sup>s<sup>−1 </sup>or less, as determined by surface plasmon view more

The neutralizing isolated human antibody of claim 29, or an antigen-binding portion thereof, which dissociates from human IL-12 with a k<sub>off </sub>rate constant of 1×10<sup>−4</sup>s<sup>−1 </sup>or less.

The neutralizing isolated human antibody of claim 29, or an antigen-binding portion thereof, which disassociates from human IL-12 with a K<sub>off </sub>rate constant of 1×10<sup>−3 </sup>s<sup>−1 </sup>or less.

A pharmaceutical composition comprising the antibody or an antigen binding portion thereof of claims 1, 16, 21, 27, 29, 41, 44, 45, 48, 50, 51, and a pharmaceutically acceptable carrier.